{'fraction_non_alphanumeric': 0.018808777429467086, 'fraction_numerical': 0.009404388714733543, 'mean_word_length': 5.520408163265306, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MP46-11 BILATERAL INGUINAL LYMPHNODE DISSECTION VERSUS INGUINAL LYMPHNODE DISSECTION AND DYNAMIC SENTINEL NODE BIOPSY IN CLINICAL N1 SQUAMOUS CELL CARCINOMA OF THE PENIS

therapies tested, regardless of PDO response to firstor second-line SOC (Figure 1B). CONCLUSIONS: This data suggests that RAPiDS could be used on TC PDOs to help guide the selection of treatment options within clinically relevant timelines, which has the potential to be useful, especially in metastatic and rare cancer settings where therapeutic options are limited. Additionally, we are currently investigating the utility of RAPiDS in refractory and metastatic TC.